These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4246 related items for PubMed ID: 3370736

  • 1. Development of alkylating agent-resistant human tumor cell lines.
    Teicher BA, Frei E.
    Cancer Chemother Pharmacol; 1988; 21(4):292-8. PubMed ID: 3370736
    [Abstract] [Full Text] [Related]

  • 2. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
    Frei E, Holden SA, Gonin R, Waxman DJ, Teicher BA.
    Cancer Chemother Pharmacol; 1993; 33(2):113-22. PubMed ID: 8261570
    [Abstract] [Full Text] [Related]

  • 3. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E.
    Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
    [Abstract] [Full Text] [Related]

  • 4. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD.
    Cancer Res; 1989 Nov 15; 49(22):6185-92. PubMed ID: 2804968
    [Abstract] [Full Text] [Related]

  • 5. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E.
    Cancer Chemother Pharmacol; 1989 Nov 15; 25(1):32-6. PubMed ID: 2590999
    [Abstract] [Full Text] [Related]

  • 6. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY.
    Cancer Res; 1988 Nov 15; 48(22):6417-23. PubMed ID: 3180059
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B.
    Anticancer Res; 1991 Nov 15; 11(4):1555-60. PubMed ID: 1746913
    [Abstract] [Full Text] [Related]

  • 8. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
    Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E.
    Cancer Res; 1987 Jan 15; 47(2):388-93. PubMed ID: 3539321
    [Abstract] [Full Text] [Related]

  • 9. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 10. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E.
    Cancer Res; 1991 Feb 15; 51(4):1086-91. PubMed ID: 1825474
    [Abstract] [Full Text] [Related]

  • 11. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA, Herman TS, Tanaka J, Dezube B, Pardee A, Frei E.
    Cancer Chemother Pharmacol; 1991 Feb 15; 28(1):45-50. PubMed ID: 1904012
    [Abstract] [Full Text] [Related]

  • 12. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E.
    Cancer Res; 1989 Nov 01; 49(21):5994-8. PubMed ID: 2790813
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
    Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E.
    Int J Cancer; 1991 Jan 21; 47(2):252-60. PubMed ID: 1846350
    [Abstract] [Full Text] [Related]

  • 14. Beta-carotene and/or vitamin E as modulators of alkylating agents in SCC-25 human squamous carcinoma cells.
    Schwartz JL, Tanaka J, Khandekar V, Herman TS, Teicher BA.
    Cancer Chemother Pharmacol; 1992 Jan 21; 29(3):207-13. PubMed ID: 1733553
    [Abstract] [Full Text] [Related]

  • 15. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA, Bernal SD, Holden SA, Cathcart KN.
    Cancer Chemother Pharmacol; 1988 Jan 21; 21(4):281-5. PubMed ID: 3131032
    [Abstract] [Full Text] [Related]

  • 16. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L, Korbut T, Herman TS, Teicher BA.
    Cancer Lett; 1991 Dec 09; 61(1):7-14. PubMed ID: 1764699
    [Abstract] [Full Text] [Related]

  • 17. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin.
    Caney C, Singh G, Lukka H, Rainbow AJ.
    Int J Radiat Biol; 2004 Apr 09; 80(4):291-9. PubMed ID: 15204706
    [Abstract] [Full Text] [Related]

  • 18. Alkylating agent resistance: in vitro studies with human cell lines.
    Frei E, Cucchi CA, Rosowsky A, Tantravahi R, Bernal S, Ervin TJ, Ruprecht RM, Haseltine WA.
    Proc Natl Acad Sci U S A; 1985 Apr 09; 82(7):2158-62. PubMed ID: 3856890
    [Abstract] [Full Text] [Related]

  • 19. Antitumor and radiosensitizing activity of several platinum-(+) dye complexes.
    Teicher BA, Holden SA.
    Radiat Res; 1987 Jan 09; 109(1):58-67. PubMed ID: 3809392
    [Abstract] [Full Text] [Related]

  • 20. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 09; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 213.